CFRX [NASD]
ContraFect Corporation
Index- P/E- EPS (ttm)-0.90 Insider Own4.87% Shs Outstand39.33M Perf Week2.53%
Market Cap122.73M Forward P/E- EPS next Y-0.98 Insider Trans0.00% Shs Float37.42M Perf Month-9.50%
Income-35.20M PEG- EPS next Q-0.33 Inst Own62.60% Short Float4.51% Perf Quarter-0.92%
Sales- P/S- EPS this Y55.40% Inst Trans-0.77% Short Ratio19.93 Perf Half Y-4.42%
Book/sh0.76 P/B4.26 EPS next Y27.50% ROA-49.00% Target Price11.92 Perf Year-17.56%
Cash/sh1.11 P/C2.91 EPS next 5Y12.70% ROE-74.30% 52W Range2.11 - 4.76 Perf YTD23.19%
Dividend- P/FCF- EPS past 5Y42.10% ROI- 52W High-31.86% Beta0.54
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low53.55% ATR0.34
Employees38 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)45.03 Volatility8.89% 9.86%
OptionableYes Debt/Eq0.00 EPS Q/Q-185.70% Profit Margin- Rel Volume0.67 Prev Close3.13
ShortableYes LT Debt/Eq0.00 EarningsMar 24 BMO Payout- Avg Volume84.75K Price3.24
Recom1.80 SMA20-6.90% SMA50-11.70% SMA200-5.21% Volume56,509 Change3.51%
Feb-02-22Upgrade WBB Securities Speculative Buy → Buy $6.50
Sep-09-21Initiated SVB Leerink Outperform $14
Jun-09-20Initiated Mizuho Buy $12
Jun-09-20Initiated Cantor Fitzgerald Overweight $15
Jul-28-16Initiated Piper Jaffray Overweight
Jul-22-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Maxim Group Buy $8 → $7
Dec-31-15Reiterated Maxim Group Buy $16 → $9
May-23-22 08:00AM  
May-20-22 08:30AM  
May-16-22 07:30AM  
Apr-27-22 09:00AM  
08:00AM  
Apr-18-22 07:30AM  
Apr-04-22 07:15AM  
Mar-24-22 08:00AM  
Mar-21-22 08:30AM  
Mar-02-22 04:20AM  
Feb-10-22 07:30AM  
Jan-06-22 04:05PM  
Jan-01-22 07:23AM  
Dec-20-21 09:00AM  
Nov-30-21 05:52AM  
Nov-15-21 07:30AM  
Nov-09-21 07:30AM  
Nov-01-21 07:11AM  
Oct-26-21 07:30AM  
Oct-12-21 06:26AM  
Oct-04-21 09:00AM  
Sep-29-21 07:30AM  
Sep-22-21 07:30AM  
Aug-30-21 07:18AM  
Aug-13-21 07:30AM  
Jul-27-21 10:27PM  
Jul-26-21 05:53AM  
Jul-19-21 07:31AM  
07:30AM  
Jun-28-21 02:54AM  
Jun-24-21 10:42AM  
Jun-17-21 07:31AM  
07:30AM  
May-26-21 07:30AM  
May-24-21 08:19AM  
May-14-21 07:30AM  
May-03-21 07:30AM  
Apr-26-21 07:30AM  
Apr-15-21 06:30PM  
Apr-09-21 06:40AM  
Mar-30-21 07:30AM  
03:00AM  
Mar-22-21 04:05PM  
Mar-17-21 04:01PM  
Mar-16-21 06:27AM  
Mar-12-21 07:36AM  
Mar-11-21 04:05PM  
Feb-11-21 07:00AM  
Dec-30-20 12:55AM  
Dec-11-20 05:59PM  
Nov-24-20 06:56AM  
Nov-13-20 08:33AM  
Oct-31-20 08:00AM  
Oct-26-20 07:00AM  
Oct-01-20 07:31AM  
Sep-09-20 07:30AM  
Aug-25-20 07:30AM  
Aug-19-20 05:50AM  
Aug-14-20 07:30AM  
Jul-20-20 07:30AM  
Jul-03-20 08:48AM  
Jun-18-20 10:56AM  
Jun-17-20 07:30AM  
Jun-15-20 07:30AM  
Jun-10-20 01:46PM  
May-29-20 06:43AM  
May-26-20 07:30AM  
May-22-20 07:10AM  
May-21-20 10:59PM  
04:09PM  
May-15-20 07:30AM  
May-11-20 07:30AM  
Apr-21-20 07:00AM  
Mar-30-20 05:00AM  
Mar-23-20 06:15AM  
Mar-21-20 09:01AM  
Mar-18-20 07:00AM  
Mar-04-20 07:00AM  
Feb-24-20 07:00AM  
Feb-18-20 03:45PM  
03:10PM  
11:25AM  
Feb-04-20 07:00AM  
Feb-03-20 07:00AM  
Jan-27-20 07:00AM  
Jan-22-20 07:00AM  
Jan-21-20 05:00AM  
Jan-13-20 08:00AM  
Jan-10-20 07:00AM  
Jan-06-20 05:30PM  
Jan-04-20 07:30AM  
Dec-20-19 10:56AM  
08:00AM  
Dec-18-19 07:00AM  
Dec-17-19 09:25AM  
Dec-16-19 07:30AM  
06:40AM  
Dec-10-19 08:46AM  
07:56AM  
Dec-09-19 04:03PM  
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.